Patent ID: 9119783
Filing Date: 2015-09-01
Classification: A61K

Abstract:
1. A method of treating a Pseudomonas aeruginosa infection in a human patient comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the lipid component of the liposomal amikacin formulation comprises dipalmitoylphosphatidylcholine (DPPC) and a sterol, the at least one treatment cycle comprises an administration period of 20 to 35 days, followed by an off period of 15 to 75 days; during which an improvement in lung function is maintained for at least 15 days after the administration period ends, wherein the improvement in lung function comprises an increase in Forced Expiratory Volume in one second (FEV and the effective dose comprises 510 mg to 610 mg of amikacin daily during the administration period.